BNC105: A novel tubulin polymerization inhibitor that selectively disrupts tumor vasculature and displays single-agent antitumor efficacy

Molecular Cancer Therapeutics

Volumn 9, Issue 6, 2010, Pages 1562-1573

  Kremmidiotis, Gabriel ^a   Leske, Annabell F ^a   Lavranos, Tina C ^a   Beaumont, Donna ^a   Gasic, Jelena ^a   Hall, Allison ^a   O'Callaghan, Michael ^a   Matthews, Clayton A ^a   Flynn, Bernard ^a  

^a Bionomics Ltd   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BNC 105; BNC 105 PHOSPHATE ESTER; CA 4; COMBRETASTATIN A4 PHOSPHATE; PACLITAXEL; PRODRUG; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CAPILLARY ENDOTHELIUM; CELL AGING; CELL MEMBRANE PERMEABILITY; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; DRUG TISSUE LEVEL; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; TISSUE DISTRIBUTION; TUMOR VASCULARIZATION;

ANIMALS; ANISOLES; ANTINEOPLASTIC AGENTS; BENZOFURANS; CAPILLARIES; CELL LINE; CELL MEMBRANE PERMEABILITY; CELL PROLIFERATION; CELL SURFACE EXTENSIONS; ENDOTHELIAL CELLS; HUMANS; MICE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; REMISSION INDUCTION; TREATMENT OUTCOME; TUBULIN MODULATORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77953423945     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0815     Document Type: Article

References (21)

1. Pellegrini F, Budman DR. Review: tubulin function, action of anti-tubulin drugs, and new drug development. Cancer Invest 2005;23:264-73. (Pubitemid 40770744)
2. Han Y, Malak H, Chaudhary AG, Chordia MD, Kingston DG, Bane S. Distances between the paclitaxel, colchicine, and exchangeable GTP binding sites on tubulin. Biochemistry 1998;37:6636-44. (Pubitemid 28228097)
3. Pasquier E, André N, Braguer D. Targeting microtubules to inhibit angiogenesis and disrupt tumour vasculature: implications for cancer treatment. Curr Cancer Drug Targets 2007;7:566-81. (Pubitemid 47358143)
4. Hait WN, Rubin E, Goodin S. Tubulin-targeting agents. Cancer Chemother Biol Response Modif 2005;22:35-59.
5. Tozer GM, Kanthou C, Baguley BC. Disrupting tumor blood vessels: tubulin-binding agents and the combretastatins. Nat Rev Cancer 2005;5:423-35.
6. Salmon B, Siemann D. Characterizing the tumor response to treatment with combretastatin A4 phosphate. Int J Radiat Oncol Biol Phys 2007;68:211-17. (Pubitemid 46589857)
7. Kanthou C, Tozer MT. Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies. Int J Path 2009;90:284-94.
8. Dowlati A, Robertson K, Cooney M, et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 2002;62:3408-16.
9. Lo Russo PM, Gadgeel SM, Wozniak A, et al. Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors. Invest New Drugs 2008;26:159-67.
10. Bussolati B, Deambrosis I, Russo S, Deregibus MC, Camussi G. Altered angiogenesis and survival in human tumor-derived endothelial cells. FASEB J 2003;17:1159-61.
11. Watts ME, Woodcock M, Arnold S, Chaplin DJ. Effects of novel and conventional anti-cancer agents on human endothelial permeability: influence of tumor secreted factors. Anticancer Res 1997;17:71-75.
12. Trotter MJ, Olive PL, Chaplin DJ. Effect of vascular marker hoechst 33342 on tumor perfusion and cardiovascular function in the mouse. Br J Cancer 1990;62:903-8.
13. Kanthou C, Tozer GM. The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 2002;99:2060-9.
14. Hua J, Sheng Y, Pinney KG, et al. Oxi4503, a novel vascular targeting agent: effects on blood flow and antitumor activity in comparison to combretastatin A-4 phosphate. Anticancer Res 2003;23:1433-40.
15. Nicholson B, Lloyd GK, Miller BR, et al. NPI-2358 is a tubulin-depolymerizing agent: in vitro evidence for activity as a tumor vascular-disrupting agent. Anticancer Drugs 2006;17:25-31.
16. Burns CJ, Harte MF, Bu X, et al. Discovery of CYT997: a structurally novel orally active microtubule targeting agent. Bioorg Med Chem Lett 2009;19:4639-42.
17. Kasibhatla S, Baichwal V, Cai SX, et al. MPC-6827: a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps. Cancer Res 2007;67:5865-71.
18. Cai SX. Small molecule vascular disrupting agents: potential new drugs for cancer treatment. Recent Pat Anticancer Drug Discov 2007;2:79-101.
19. Cai SX, Drewe J, Kemnitzer W. Discovery of 4-aryl-4H-chromenes as potent apoptosis inducers using a cell- and caspase-based anti-cancer screening apoptosis program (ASAP): SAR studies and the identification of novel vascular disrupting agents. Anticancer Agents Med Chem 2009;9:437-56.
20. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ. Combretastatin A-4, an agent that displays potent and selective toxicity towards tumor vasculature. Cancer Res 1997;57:1829-34.
21. El-Emir E, El-Emir E, Boxer GM, et al. Tumour parameters affected by combretastatin A-4 phosphate therapy in a human colorectal xenograft model in nude mice. Eur J Cancer 2005;41:799-806.